1020719-86-1
1020719-86-1
Chemical Structure
Sulfamethoxazole-d4
Synonym(s): Ro 4-2130-d4
- CAS No.: 1020719-86-1
- Formula:C10H7D4N3O3S
- Molecular Weight:257.30
IUPAC Name: 4-amino-N-(5-methylisoxazol-3-yl)benzene-2,3,5,6-d4-sulfonamide
InChIKey: JLKIGFTWXXRPMT-QFFDRWTDSA-N
SMILES: O=S(C1=C([2H])C([2H])=C(N)C([2H])=C1[2H])(NC2=NOC(C)=C2)=O
Biological Activity: Sulfamethoxazole-d4 (Ro 4-2130-d4) is a deuterium labeled Sulfamethoxazole (HY-B0322). Sulfamethoxazole (Ro 4-2130) is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Sulfamethoxazole-d4 | 98.22% | Sulfamethoxazole-d4 (Ro 4-2130-d4) is a deuterium labeled Sulfamethoxazole (HY-B0322). Sulfamethoxazole (Ro 4-2130) is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamethoxazole (Standard) | 99.98% | Sulfamethoxazole (Standard) (Ro 4-2130 (Standard)) is the analytical standard of Sulfamethoxazole (HY-B0322). This product is intended for research and analytical applications. Sulfamethoxazole (Ro 4-2130) is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamethoxazole-13C6 | 99.91% | Sulfamethoxazole-13C6 (Ro 4-2130-13C6) is a 13C labeled Sulfamethoxazole (HY-B0322). Sulfamethoxazole (Ro 4-2130) is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamethoxazole 1000 µg/mL in methanol | Sulfamethoxazole (Ro 4-2130) 1000 μg/mL in methanol is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole 1000 μg/mL in methanol inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole 1000 μg/mL in methanol can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Sulfamethoxazole | 99.70% | Sulfamethoxazole (Ro 4-2130) is a sulfonamide antibiotic with a widespread antibacterial activity. Sulfamethoxazole inhibits bacterial folate metabolism by competing with 4-Aminobenzoic acid (HY-B1008) (PABA) to act on dihydropteroate synthetase and dihydropteroate reductase. Sulfamethoxazole can be used for the study of urinary tract infections (UTIs), prostatitis, and bronchitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zambuzzi-Carvalho et al. Transcriptional profile of the human pathogenic fungus Paracoccidioides lutzii in response to sulfamethoxazole. Med Mycol. 2015;53(5):477-492. [Content Brief]
- [2]. Choonara BF, et al. A menthol-based solid dispersion technique for enhanced solubility and dissolution of sulfamethoxazole from an oral tablet matrix. AAPS PharmSciTech. 2015 Aug;16(4):771-86. [Content Brief]
- [3]. Ogata H, et al. Dose Dependent Effect of Sulfamethoxazole on Inhibiting KATP Channel of Mouse Pancreatic β Cell. Dose Response. 2023 Sep 28;21(3):15593258231203611. [Content Brief]
